Remedy has not only worked tra­di­tion­ally on one game at a time, it’s of­ten been wed­ded to a sin­gle plat­form, part-funded by the plat­form holder. Does the change in stu­dio struc­ture mean a change in that ap­proach too? “Of course, as a cre­ative com­pany, you want to reach as big an au­di­ence as pos­si­ble,” Puha says. “So you want to be out on as many plat­forms as you can. But when you’re ex­clu­sive to one or two plat­forms, or al­most a first­party game like we were with Mi­crosoft [for

Quan­tumBreak], there are a lot of ben­e­fits. There are a lot of op­por­tu­ni­ties these days for in­de­pen­dent devel­op­ers to get fund­ing. It’s a com­pli­cated space, sure, but with a lot of op­por­tu­ni­ties.” Remedy isn’t say­ing much about its two cur­rent projects, but we do know it’s try­ing some­thing dif­fer­ent on one of them, sign­ing up with a pub­lisher it’s never worked with be­fore. Thir­teen years on from MaxPayne2, could Remedy fi­nally re­turn to PlaySta­tion?

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.